EUCTR2006-003243-23-ITActive, not recruitingNot Applicable
A Phase II Study of OXALIPLATIN and GEMCITABINE in Combination with IFOSFAMIDE plus RITUXIMAB (R-GIFOX) as 2nd-line Chemotherapy in Relapsed and Primary Refractory Lymphoma - R-GIFOX
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE0 sitesStarted: June 15, 2007Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •4.1.1Patients must have histologically confirmed diagnosis of lymphoma of the following subtypes according to REAL/WHO ,
- •Non-Hodgkin's lymphomas
- •?Diffuse Large B Cell Lymphoma (DLBCL) and variants
- •?Anaplastic Large Cell Lymphoma (ALCL) B/null
- •?Mantle Cell Lymphoma (MCL)
- •?Follicular Cell Lymphoma (FCL) Grade 3
- •?Histologic Transformation of previous indolent lymphomas
- •Hodgkin's disease
- •?Classic Hodgkin's Lymphoma including lymphocyte rich category
- •4.1.2Patient must be relapsing to or primary progressive while on 1st-line induction anthracycline-containing chemotherapy with and without immunotherapy (Rituximab) and/or radiotherapy
- •4.1.3Patients must have measurable disease, defined according criteria detailed in Section 12.
- •4.1.4Age >18 years
- •4.1.5Life expectancy of greater than 3 months.
- •4.1.6ECOG performance status <2; see Appendix A.
- •4.1.7Patients must have normal organ and marrow function as defined below:
- •-Absolute neutrophil count>1,500/mL
- •-Platelets>100,000/mL
- •-Total bilirubinwithin normal institutional limits
- •-AST (SGOT)/ALT (SGPT)<2.5 X institutional upper limit of normal
- •-creatininewithin normal institutional limits or Creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal, as calculated by using the Cockcroft-Gault formula:
- •(140 ? Age) x Weight (kg) x [1-(0.15 x Sex)]
- •0.814 x Serum Creatinine (mg/dL)
- •Sex: Male=0; Female=1
- •4.1.8Ability to understand and the willingness to sign a written informed consent document including consent for ASCT in patients aged <=.65 years.
- •4.1.9The effects of Oxaliplatin and Gemcitabine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because Cisplatin analogs agents as well as other therapeutic agents used in this trial (i.e. and Ifosfamide) are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •4.2.1Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- •4.2.2Patients may not be receiving any other investigational agents.
- •4.2.3Patients with known lymphoma brain localization should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurological and other adverse events.
- •4.2.4History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in the study.
- •4.2.5Uncontrolled intercurrent illness including, but not limited to, ongoing active infection (including hepatitis B), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrollable metabolic disease, or psychiatric illness/social situations that would limit compliance with study requirements.
- •4.2.6Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects of agents employed.
- •4.2.7Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy. Therefore, HIV-positive patients are excluded.
- •4.2.8More than one month between staging procedures and the start of the treatment
Investigators
Similar Trials
Completed
Phase 2
Phase II study of gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced biliary tract cancer (JASPAC02)gemcitabine refractory advanced biliary tract cancerJPRN-UMIN000003650Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)40
Completed
Not Applicable
A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy.pper rectal cancerJPRN-UMIN000015765Cancer Institute Hospital of Japanese Foundation for Cancer Research19
Terminated
Phase 2
Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial TractCarcinoma, Transitional CellNCT00127595Gustave Roussy, Cancer Campus, Grand Paris28
Completed
Phase 2
Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the UterusMixed Mullerian Tumors of the UterusNCT00476086Dana-Farber Cancer Institute20
Active, not recruiting
Phase 1
Fase II trial with gemcitabine and oxaliplatin in patients with unknown primary tumours - UPT - unfitTo test the effect of Gemcitabine and axaliplatin in patients with unknown primary tumours and performance 2 or age 66 to 75EUCTR2005-001959-38-DKGedske Daugaard39